DEXA Scan Recommendations for Osteoporosis Screening and Management

Initial Screening Recommendations

The American College of Radiology recommends DXA of the lumbar spine and hip(s) as the primary modality for osteoporosis screening in women ≥65 years, men ≥70 years, and younger individuals with specific risk factors 1
The European Journal of Nuclear Medicine and Molecular Imaging suggests that postmenopausal women and men ≥50 years with risk factors such as previous fragility fracture, chronic glucocorticoid therapy, or chronic inflammatory conditions should undergo initial DEXA screening 2, 1
Premenopausal women and men <50 years should only undergo DEXA screening if they have medical conditions or medications that adversely affect bone density, as recommended by the Journal of the American College of Radiology 2, 6

The Journal of Clinical Oncology recommends that the preferred assessment uses DXA of the total spine, hip, and femoral neck for a comprehensive evaluation of fracture risk 3, 4, 5
For patients with advanced degenerative spine changes or scoliosis, the Journal of the American College of Radiology suggests using DXA of the distal forearm or quantitative CT (QCT) of the lumbar spine and hip instead 7, 8, 9

The Journal of the American College of Radiology recommends a standard monitoring interval of every 2 years for both treated and untreated patients 2, 3, 4, 5
The Journal of Clinical Oncology suggests an accelerated interval of every 1 year for patients at high risk of rapid bone loss, such as those initiating osteoporosis therapy or receiving glucocorticoid therapy 2, 5

The European Journal of Nuclear Medicine and Molecular Imaging recommends performing VFA concomitantly with DXA in patients with T-scores <-1.0 and one or more of the following: women ≥70 years or men ≥80 years, historical height loss >4 cm, self-reported but undocumented prior vertebral fracture, or glucocorticoid therapy ≥5 mg prednisone equivalent daily for ≥3 months 1, 9
The Journal of the American College of Radiology highlights the utility of VFA, as 50% of fragility fractures occur in postmenopausal women with T-scores >-2.5, and identification of vertebral fractures can reclassify patients who would otherwise not qualify for treatment based solely on BMD measurements 2

The Journal of Clinical Oncology recommends repeat DXA every 2 years or as clinically indicated for cancer survivors on aromatase inhibitors, androgen deprivation therapy, or those with chemotherapy-induced ovarian failure 3, 4, 5
The Journal of the American College of Radiology suggests using Z-scores (not T-scores) for interpretation in premenopausal women and men <50 years, as WHO criteria do not apply to this population 2
The Journal of the American College of Radiology recommends one-year follow-up intervals for patients on glucocorticoids due to the risk of substantial short-term decreases in mineralization 2

The Journal of the American College of Radiology advises against using peripheral DXA or QUS for diagnosis in standard populations, as these are screening tools only and cannot be interpreted using WHO criteria 9
The Journal of Clinical Oncology and the Journal of the American College of Radiology recommend against scanning more frequently than annually, as the precision of DXA measurements and the rate of bone turnover make more frequent scanning clinically unhelpful 2, 3, 4, 5
The Journal of the American College of Radiology warns against comparing scans from different DXA machines without cross-calibration 2
The Journal of the American College of Radiology advises against relying solely on spine DXA in patients with degenerative disease, as spuriously elevated BMD from spondylosis occurs in >81% of falsely elevated measurements 9